• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Overview of Efalizumab Open-label Trials

Article

An open-label study was undertaken to evaluate the safety, tolerability, and efficacy of continuous efalizumab therapy in patients achieving PASI 50 or an OLS grade of Mild, Minimal, or Clear at 12 weeks of therapy.

Related Videos
Related Content
Half of Patients With Psoriasis Receiving Placebo In Clinical Trials Report Adverse Events

Half of Patients With Psoriasis Receiving Placebo In Clinical Trials Report Adverse Events

Article
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

Podcast
Mobile Health Technologies In Studies of Actinic Keratosis Do Not Compromise Patient Safety, Research Article Says

Mobile Health Technologies In Studies of Actinic Keratosis Do Not Compromise Patient Safety, Research Article Says

Article
ReV Up Your Vitiligo Treatment Strategies

ReV Up Your Vitiligo Treatment Strategies

Podcast
Introducing Omar Noor, MD, FAAD: Dermatology Times' Newest Editorial Advisory Board Member

Introducing Omar Noor, MD, FAAD: Dermatology Times' Newest Editorial Advisory Board Member

Article
Atopic Dermatitis Identified as Possible Risk Factor for Headache Disorders, Migraine

Atopic Dermatitis Identified as Possible Risk Factor for Headache Disorders, Migraine

Article
© 2024 MJH Life Sciences

All rights reserved.